BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

J Psychopharmacol. 2012 Jul;26(7):899-952. doi: 10.1177/0269881112444324. Epub 2012 May 23.

Abstract

The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Combined Modality Therapy
  • Comorbidity
  • Diagnostic and Statistical Manual of Mental Disorders
  • Evidence-Based Medicine*
  • Female
  • Humans
  • Male
  • Mental Disorders / drug therapy*
  • Mental Disorders / epidemiology
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Pregnancy Complications / epidemiology
  • Psychotherapy
  • Substance Withdrawal Syndrome / drug therapy
  • Substance Withdrawal Syndrome / epidemiology
  • Substance-Related Disorders / drug therapy*
  • Substance-Related Disorders / epidemiology
  • Substance-Related Disorders / therapy
  • United Kingdom